- $2.10bn
- $1.94bn
- $276.26m
Vericel Corp reports results for the quarter ended June 30 - Earnings Summary
Vericel beats Q2 revenue estimates, boosts annual outlook
Brief: Vericel Q2 EPS USD 0.04
Vericel beats Q1 revenue on MACI, burn care growth, lifts 2026 sales outlook
Brief: Vericel Secures $197 Mln BARDA Award For Advanced Development Of NexoBrid
Brief: Vericel Announces FDA Approval Of New State-Of-The-Art Advanced Therapy Manufacturing Facility
Vericel Q4 revenue rises 23%, beats estimates
Sports and burn therapies firm Vericel Q3 revenue beats estimates
Vericel Corp reports results for the quarter ended June 30 - Earnings Summary
Biologics company Vericel's Q2 revenue misses expectations
Vericel Corp reports results for the quarter ended March 31 - Earnings Summary
Brief: Vericel Corp - Anticipates Minimal Impact From New Tariffs - SEC Filing
Vericel Corp reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-Abbvie, Comstock Resources, Sherwin-Williams
Vericel falls as prelim Q4 revenue misses estimates
Brief: Vericel Q4 Gross Margin 77%
Vericel Corp reports results for the quarter ended in September 30 - Earnings Summary
Brief: Vericel Q3 EPS USD -0.02
Brief: Vericel Announces FDA Approval And Commercial Availability Of Maci Arthro